These in vitro and in vivo results and an earlier report [16] collectively suggest that fatostatin not only exhibits anti-tumor activity in AR-positive PCa cells but also shows efficacy on metastatic AR-negative PCa with p53 mutations. Here, AR is linked to neoplasm.